These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24399309)

  • 1. Intravenous immunoglobulin for prophylaxis of acute exacerbation in Myasthenia Gravis.
    Sorgun MH; Sener HO; Yucesan C; Yucemen N
    Neurol Sci; 2014 Jun; 35(6):891-6. PubMed ID: 24399309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulin G treatment of myasthenia gravis.
    Ferrero B; Durelli L
    Neurol Sci; 2002 Apr; 23 Suppl 1():S9-24. PubMed ID: 12032583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka K
    Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin monotherapy in long-term treatment of myasthenia gravis.
    Wegner B; Ahmed I
    Clin Neurol Neurosurg; 2002 Dec; 105(1):3-8. PubMed ID: 12445915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
    Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
    Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of repeated doses of intravenous immunoglobulin in myasthenia gravis.
    Arsura EL; Bick A; Brunner NG; Grob D
    Am J Med Sci; 1988 May; 295(5):438-43. PubMed ID: 3376987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic low-dose intravenous immunoglobulins as steroid-sparing therapy in myasthenia gravis.
    Wilf-Yarkoni A; Lotan I; Steiner I; Hellmann MA
    J Neurol; 2021 Oct; 268(10):3871-3877. PubMed ID: 33829320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
    Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
    J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin for myasthenia gravis.
    Gajdos P; Chevret S; Toyka KV
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world utilization patterns of intravenous immunoglobulin in adults with generalized myasthenia gravis in the United States.
    Qi CZ; Hughes T; Gelinas D; Li Y; Goyal A; Brauer E; Bhuwalka A; Sato M; Jadhav S; Phillips G
    J Neurol Sci; 2022 Dec; 443():120480. PubMed ID: 36347174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
    Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
    Wolfe GI; Barohn RJ; Foster BM; Jackson CE; Kissel JT; Day JW; Thornton CA; Nations SP; Bryan WW; Amato AA; Freimer ML; Parry GJ;
    Muscle Nerve; 2002 Oct; 26(4):549-52. PubMed ID: 12362423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
    Gajdos P; Chevret S
    Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial in acetylcholine receptor antibody-positive myasthenia gravis of transition from intravenous to subcutaneous immunoglobulin: The MGSCIg study.
    Pasnoor M; Bril V; Levine T; Trivedi J; Silvestri NJ; Phadnis M; Katzberg HD; Saperstein DS; Wolfe GI; Herbelin L; Higgs K; Heim AJ; Statland JM; Barohn RJ; Dimachkie MM
    Eur J Neurol; 2023 May; 30(5):1417-1424. PubMed ID: 36779862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary spastic angina after the administration of intravenous immunoglobulin in myasthenia gravis: a case report.
    Yanagihashi M; Okamoto R; Morioka H; Sawada M; Matsumoto S; Ikeda T; Kano O
    BMC Neurol; 2020 Aug; 20(1):319. PubMed ID: 32859168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin treatment in refractory Myasthenia gravis.
    Achiron A; Barak Y; Miron S; Sarova-Pinhas I
    Muscle Nerve; 2000 Apr; 23(4):551-5. PubMed ID: 10716766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When do we judge IVIg for myasthenia gravis ineffective?
    Takizawa T; Suzuki S; Suzuki N
    Neurol Sci; 2015 Jul; 36(7):1295-7. PubMed ID: 25511979
    [No Abstract]   [Full Text] [Related]  

  • 20. Dyshidrotic eczema associated with the use of IVIg.
    Kotan D; Erdem T; Acar BA; Boluk A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.